Alector Inc (NASDAQ:ALEC)
| 7.42 Delayed Data As of Jun 06 |  +0.23 / +3.20%Today’s Change | 5.76 Today|||52-Week Range 13.50 | -19.61% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $593.5M |
Company Description
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.
Contact Information
Alector, Inc. 131 Oyster Point Boulevard South San Francisco California 94080-2029 |
Employees
Shareholders
| Individual stakeholders | 36.65% |
| Mutual fund holders | 36.51% |
| Other institutional | 33.44% |
Top Executives
| Arnon Rosenthal | Chief Executive Officer & Director |
| Saraswati Kenkare-Mitra | President, Head-Research & Development |
| Marc Edward Grasso | Chief Financial, Accounting & Business Officer |
| Charles Wolfus | VP-Technology & Digital Health |
| Gary Romano | Chief Medical Officer |
